Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (AU:SNT)
ASX:SNT
Pharmaxis Ltd (SNT) Share Price & Analysis
1 Followers
SNT Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.01 - AU$0.06
Previous CloseAU$0.02
Volume8.50K
Average Volume (3M)1.86M
Market Cap
AU$31.26M
Enterprise ValueAU$24.01M
Total Cash (Recent Filing)AU$8.94M
Total Debt (Recent Filing)AU$4.29M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 14, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding722,614,210
10 Day Avg. Volume2,290,257
30 Day Avg. Volume1,860,380
Standard Deviation0.14
R-Squared0.03
Alpha-0.00747
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pharmaxis Ltd News
PremiumCompany Announcements
Pharmaxis Ltd Projects Future Amidst Uncertainties
PremiumCompany Announcements
Syntara CEO to Present at Life Sciences Webinar
PremiumCompany Announcements
Syntara Limited Showcases at Investor Webinar
PremiumCompany Announcements
Syntara Limited Announces New ASX Securities
PremiumCompany Announcements
Pharmaxis Outlines Potential Amidst UncertaintiesPremiumCompany Announcements
Pharmaxis Ltd’s Aspirations Amidst Uncertainties
PremiumCompany Announcements
Pharmaxis Ltd Advances Clinical Trials, Boosts SavingsPremiumCompany Announcements
Syntara Limited Hosts Q2 Investor BriefingOptions Prices
Currently, No data available
---
Ownership Overview
4.52% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
95.48% Public Companies and
Individual Investors
SNT FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Pharmaxis Ltd lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Pharmaxis Ltd’s market cap?
Currently, no data Available
When is Pharmaxis Ltd’s upcoming earnings report date?
Pharmaxis Ltd’s upcoming earnings report date is Aug 14, 2024 which is in 41 days.
How were Pharmaxis Ltd’s earnings last quarter?
Pharmaxis Ltd released its earnings results on Feb 29, 2024. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Overvalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Pharmaxis Ltd has 1,194,031,700 shares outstanding.
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Pharmaxis Ltd reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in AU:SNT
---
Pharmaxis Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-51.02%
12-Months-Change
Fundamentals
Return on Equity
-130.21%
Trailing 12-Months
Asset Growth
-55.23%
Trailing 12-Months
Company Description
Pharmaxis Ltd
Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.
---
SNT Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering SNT
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-46.60%
reiterated a buy rating 11 months ago
Copying Derek Jellinek's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.60% per trade.
---